WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Apotex Inc ...

Novartis announced that Tasigna (nilotinib) 150 mg capsules has been approved by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...

EAST HANOVER, N.J., March 22, 2018 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna ® (nilotinib) to include treatment ...

TASIGNA is an import treatment for chronic myeloid leukemia (CML), with worldwide sales in 2022 approaching $2.0 billion, despite a labeled warning for food interactions and a boxed warning in the US ...

Tasigna continues to surpass Glivec as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to a statement issued ...

ZURICH (MarketWatch) -- Novartis AG NVS Wednesday said that Tasigna, a potential follow-up to Gleevec, the Swiss drugmaker's second best-selling drug, won European Union approval for the treatment ...